Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

533 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.
Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Cokkinos DV, Simoons ML, Boersma E, Topol EJ, Califf RM, Harrington RA. Kleiman NS, et al. Among authors: simoons ml. Circulation. 2000 Feb 22;101(7):751-7. doi: 10.1161/01.cir.101.7.751. Circulation. 2000. PMID: 10683348 Clinical Trial.
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska J, Widimsky P, Boland JB, Armstrong PW. Alexander JH, et al. Among authors: simoons ml. Am J Cardiol. 1999 Apr 15;83(8):1147-51. doi: 10.1016/s0002-9149(99)00049-1. Am J Cardiol. 1999. PMID: 10215274 Clinical Trial.
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay CM, Lincoff AM, Deckers J, Topol EJ, Califf RM. Mahaffey KW, et al. Among authors: simoons ml. Circulation. 1999 May 11;99(18):2371-7. doi: 10.1161/01.cir.99.18.2371. Circulation. 1999. PMID: 10318656 Clinical Trial.
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
Akkerhuis KM, Deckers JW, Boersma E, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, Lincoff AM, Keltai M, Topol EJ, Califf RM, Simoons ML. Akkerhuis KM, et al. Among authors: simoons ml. Eur Heart J. 2000 Mar;21(5):371-81. doi: 10.1053/euhj.1999.1743. Eur Heart J. 2000. PMID: 10666351 Clinical Trial.
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Boersma E, et al. Among authors: simoons ml. Circulation. 2000 Jun 6;101(22):2557-67. doi: 10.1161/01.cir.101.22.2557. Circulation. 2000. PMID: 10840005 Clinical Trial.
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, Pepine CJ, Kopecky SL, Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ. Lincoff AM, et al. Among authors: simoons ml. Circulation. 2000 Sep 5;102(10):1093-100. doi: 10.1161/01.cir.102.10.1093. Circulation. 2000. PMID: 10973836 Clinical Trial.
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ. Roe MT, et al. Among authors: simoons ml. Circulation. 2000 Sep 5;102(10):1101-6. doi: 10.1161/01.cir.102.10.1101. Circulation. 2000. PMID: 10973837
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, Berdan LG, Guerci A, Cokkinos DV, Kitt MM, Lincoff AM, Topol EJ, Califf RM, Ohman EM. Greenbaum AB, et al. Among authors: simoons ml. J Am Coll Cardiol. 2001 Feb;37(2):492-8. doi: 10.1016/s0735-1097(00)01143-8. J Am Coll Cardiol. 2001. PMID: 11216968 Free article. Clinical Trial.
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, Lincoff AM; Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Lauer MA, et al. Among authors: simoons ml. Circulation. 2001 Dec 4;104(23):2772-7. doi: 10.1161/hc4801.100358. Circulation. 2001. PMID: 11733393 Clinical Trial.
533 results